GlassScriptPhysician profile
Kayann A Wilson
NPI 1952371908
$4,477.43
in general payments reported to CMS, 2019-2025
28 companies · $2,224 in 2025
The $2,224 reported for 2025 was more than what 94% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2023: $775 · 2024: $1,353 · 2025: $2,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,352.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,024.24 | 2023-2025 | |
| Sk Life Science, INC. | $429.94 | 2023-2025 | Xcopri |
| Alexion Pharmaceuticals, INC. | $420.85 | 2023-2025 | Ultomiris |
| Ucb, INC. | $369.06 | 2023-2025 | Rystiggo, Briviact, Nayzilam |
| Argenx US, INC. | $296.42 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $278.11 | 2023-2025 | Kisunla, Amyvid, Emgality |
| Eisai INC. | $172.37 | 2023-2025 | |
| Lundbeck LLC | $169.28 | 2023-2025 | Vyepti |
| Emd Serono, INC. | $161.96 | 2023-2025 | Mavenclad |
| Neurocrine Biosciences, INC. | $142.75 | 2023-2024 | Ingrezza, Ongentys |
| Otsuka America Pharmaceutical, INC. | $141.73 | 2025 | Rexulti |
| Avanir Pharmaceuticals, INC. | $124.96 | 2021 | |
| Pfizer INC. | $100.37 | 2023-2025 | |
| Axsome Therapeutics, INC. | $92.60 | 2025 | Symbravo |
| Biogen, INC. | $79.26 | 2023-2024 | Vumerity |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $74.20 | 2024-2025 | |
| Merz Pharmaceuticals, LLC | $62.22 | 2025 | Inbrija, Xeomin |
| Janssen Biotech, INC. | $60.51 | 2025 | |
| Alnylam Pharmaceuticals INC. | $48.47 | 2023 | Onpattro |
| Celgene Corporation | $41.34 | 2025 | Zeposia |
| Tanabe Pharma America, INC. | $36.04 | 2025 | Radicava |
| Globus Medical, INC. | $26.38 | 2025 | Senza |
| Life Molecular Imaging LTD | $24.08 | 2023 | Neuraceq |
| Acadia Pharmaceuticals INC | $22.84 | 2024 | Nuplazid |
| Azurity Pharmaceuticals, INC. | $21.25 | 2025 | Zonisade |
| Grifols USA, LLC | $19.78 | 2025 | Gamunex-C |
| Mallinckrodt Hospital Products INC. | $18.76 | 2025 | Acthar |
| Teva Pharmaceuticals USA, INC. | $17.66 | 2025 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayann Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.